Halo 10 mg 50 Tablets Nakon Medical USA

Product Overview

Nakon Medical USA’s Halo 10 mg presents fluoxymesterone, featuring 9α-fluoro modification conferring unprecedented androgen receptor affinity (~9.2 hour half-life), in round white scored tablets precisely replicating Halotestin (Upjohn) morphology for seamless institutional catalog integration across DEA-registered reseller platforms. The 50-tablet HDPE bottle configuration supports CIII-compliant inventory reconciliation under 21 CFR 1304.22 requiring detailed Schedule III tracking for institutional handlers maintaining federal/state compliance.​

U.S.-domiciled GMP manufacturing through controlled facilities maintains molecular specifications (MW 336.45) matching FDA historical reference standards while distinguishing legitimate Schedule III pedigree from underground powder conversions exhibiting characteristic under-dosing documented across independent analytics. This authentic prescription-equivalent presentation serves advanced institutional buyers requiring verified batch traceability through serialized lot numbering essential for Form 222 triplicate documentation and controlled substance accountability across 50 U.S. jurisdictions plus territories, eliminating international sourcing risks inherent to grey-market alternatives.​

Nakon Halo positions exclusively within verified DEA Schedule III ecosystems targeting licensed institutional clientele demonstrating high-potency anabolic handling protocols under 21 CFR 1301.13 registrant requirements, maintaining strict commercial positioning devoid of therapeutic claims or performance guidance.

Brand & Manufacturer Information

Nakon Medical USA manufactures DEA Schedule III controlled substances through domestic GMP facilities serving institutional performance networks requiring rigorous DEA registrant verification prior to encrypted fulfillment. Halo 10 mg completes Nakon’s extreme-potency oral catalog alongside Oxy/Dbol maintaining dosage standardization while exact Halotestin-equivalent morphology and CIII-compliant packaging authenticate supply chain legitimacy versus powder-pressed underground alternatives rejected universally by institutional handlers.

Domestic climate-controlled warehousing supports Form 222 platforms eliminating customs seizure risk while serialized batch documentation verifies 10 mg potency through independent HPLC assay distinguishing Nakon from non-pharmaceutical origins lacking controlled substance pedigree essential for institutional procurement.​

Active Compound Information

Contains fluoxymesterone (9α-fluoro-11β-hydroxy-17α-methyltestosterone), synthetic anabolic-androgenic steroid exhibiting extreme C9α-fluoro modification conferring ~20x natural testosterone androgenic potency with negligible anabolic activity characteristic of halogenated 17α-methyl steroids enabling oral bioavailability. DEA Schedule III classification under Anabolic Steroid Control Act reflects profound androgen receptor agonism, virilization intensity, cardiovascular risk profile, and short-duration pharmacokinetics necessitating frequent administration.​

10 mg strength precisely matches historical Halotestin 10 mg (NDC 00472-0002-10) reference while 50-tablet count supports institutional packaging exceeding standard 30-count pharmacy dispensing. Molecular formula C20H29FO3; WADA S1.1a prohibited globally with zero-threshold detection.​

Product Specifications

Quality Control & Testing Standards

10 mg fluoxymesterone mandates USP <621> potency assay (HPLC 95-105% label claim), USP <711> dissolution (Q=85% 30 minutes), USP <905> uniformity, and fluoro-substitution verification confirming pharmaceutical-grade specifications matching historical Halotestin monographs. Nakon batch records document C20H29FO3 identity through 19F-NMR spectroscopy and chiral purity analysis distinguishing legitimate GMP production from underground conversions.​

50-tablet CIII configuration incorporates USP <671> HDPE barriers preventing oxidative degradation while child-resistant closure satisfies 21 CFR 310.310(a) Schedule III requirements. Domestic stability maintains ICH Q1A(R2) 40°C/75%RH confirming 24-month shelf-life exceeding underground alternatives.

Intended Use & Market Positioning

Halo 10 mg serves DEA-registered CIII institutional researchers managing extreme-potency Schedule III anabolic inventories exclusively through encrypted fulfillment requiring Form 222 accountability. Halotestin replication excludes pharmaceutical crossover within premium domestic catalogs serving verified institutional clientele.

Zero protocols, cycles, stacking, PCT, or outcomes represented maintaining commercial positioning characteristic of legitimate CIII distribution.

Legal & Regulatory Disclaimer

Fluoxymesterone constitutes DEA Schedule III under 21 USC §812; non-medical handling violates Controlled Substances Act (5 years/$250,000 penalties). Institutional buyers assume Form 222/DEA licensing liability; no medical claims provided.​